{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:09:43Z","timestamp":1781788183366,"version":"3.54.5"},"reference-count":142,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001605","name":"Epilepsy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001605","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.molmed.2019.08.005","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T08:27:17Z","timestamp":1568276837000},"page":"1094-1109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Antibody-Mediated Enzyme Therapeutics and Applications in Glycogen Storage Diseases"],"prefix":"10.1016","volume":"25","author":[{"given":"Zhengqiu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9122-1022","authenticated-orcid":false,"given":"Grant L.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin D.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5253-9049","authenticated-orcid":false,"given":"Matthew S.","family":"Gentry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2019.08.005_bb0005","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2174\/1389450117666151209120139","article-title":"Delivery of therapeutic proteins: challenges and strategies","volume":"17","author":"Rehman","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.molmed.2019.08.005_bb0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2016.11.004","article-title":"The state-of-play and future of antibody therapeutics","volume":"122","author":"Elgundi","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molmed.2019.08.005_bb0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/ijms17040561","article-title":"Linkers having a crucial role in antibody\u2013drug conjugates","volume":"17","author":"Lu","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2019.08.005_bb0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4161\/mabs.22854","article-title":"Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates","volume":"5","author":"Ritchie","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.molmed.2019.08.005_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/mabs.27022","article-title":"Site-specific antibody drug conjugates for cancer therapy","volume":"6","author":"Panowski","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.molmed.2019.08.005_bb0030","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2005.05872.x","article-title":"The role of gemtuzumab ozogamicin in acute leukaemia therapy","volume":"132","author":"Tsimberidou","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0035","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with\u00a0acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2019.08.005_bb0040","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2018.205948","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with\u00a0perhaps more to come","volume":"104","author":"Hitzler","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.molmed.2019.08.005_bb0050","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0055","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab\u2013DM1, an antibody\u2013cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2019.08.005_bb0060","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11523-018-0584-z","article-title":"Inotuzumab ozogamicin: a review in relapsed\/refractory B cell acute lymphoblastic leukaemia","volume":"13","author":"Al-Salama","year":"2018","journal-title":"Target. Oncol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0065","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.4049\/jimmunol.164.11.6020","article-title":"Novel protein transfection of primary rat cortical neurons using an antibody that penetrates living cells","volume":"164","author":"Weisbart","year":"2000","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0070","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1021\/acs.molpharmaceut.8b01278","article-title":"Linear desferrichrome-linked silicon\u2212rhodamine antibody conjugate enables targeted multimodal imaging of HER2 in\u00a0vitro and in\u00a0vivo","volume":"16","author":"Ahn","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.molmed.2019.08.005_bb0075","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1042\/bj3560867","article-title":"Conjugation of an antibody Fv fragment to a virus coat protein: cell-specific targeting of recombinant polyoma-virus-like particles","volume":"356","author":"Stubenrauch","year":"2001","journal-title":"Biochem. J."},{"key":"10.1016\/j.molmed.2019.08.005_bb0080","doi-asserted-by":"crossref","first-page":"59965","DOI":"10.18632\/oncotarget.11015","article-title":"A lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.molmed.2019.08.005_bb0085","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody\u2013drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.molmed.2019.08.005_bb0090","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","article-title":"Fusion protein linkers: property, design and functionality","volume":"65","author":"Chen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molmed.2019.08.005_bb0095","first-page":"1061","article-title":"Biodistribution properties of 111indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab\u2032)2 constructs in a breast carcinoma xenograft model","volume":"7","author":"Tahtis","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2019.08.005_bb0100","first-page":"1288","article-title":"Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention","volume":"63","author":"Graff","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2019.08.005_bb0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/bc030018+","article-title":"Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand","volume":"15","author":"Albrecht","year":"2004","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.molmed.2019.08.005_bb0110","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00063030-200620030-00002","article-title":"Monomeric Fc fusions: impact on pharmacokinetic and biological activity\u00a0of protein therapeutics","volume":"20","author":"Dumont","year":"2006","journal-title":"BioDrugs"},{"key":"10.1016\/j.molmed.2019.08.005_bb0115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1517\/14712598.8.4.491","article-title":"Etanercept","volume":"8","author":"Ducharme","year":"2008","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.molmed.2019.08.005_bb0120","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.molmed.2019.08.005_bb0125","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1529-8019.2007.00140.x","article-title":"Alefacept for the treatment of psoriasis and other dermatologic diseases","volume":"20","author":"Strober","year":"2007","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.molmed.2019.08.005_bb0130","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1358\/dot.2009.45.6.1378935","article-title":"Rilonacept in the treatment of chronic inflammatory disorders","volume":"45","author":"McDermott","year":"2009","journal-title":"Drugs Today"},{"key":"10.1016\/j.molmed.2019.08.005_bb0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1749-6632.2011.05975.x","article-title":"The development of romiplostim for patients with immune thrombocytopenia","volume":"1222","author":"Molineux","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.molmed.2019.08.005_bb0140","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.molmed.2019.08.005_bb0145","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2174\/187152811798104872","article-title":"Aflibercept (VEGF-TRAP): the next anti-VEGF drug","volume":"10","author":"Stewart","year":"2011","journal-title":"Inflamm. Allergy - Drug Targets"},{"key":"10.1016\/j.molmed.2019.08.005_bb0150","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00262-012-1286-5","article-title":"Phase II trial of hu14.18-IL2 for patients with metastatic melanoma","volume":"61","author":"Albertini","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.molmed.2019.08.005_bb0155","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1200\/JCO.2009.27.8861","article-title":"Antitumor activity of hu14.18-IL2 in patients with relapsed\/refractory neuroblastoma: a Children\u2019s Oncology Group\u00a0(COG) phase II study","volume":"28","author":"Shusterman","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0160","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1158\/1078-0432.CCR-10-2490","article-title":"A phase 1 study of AS1409, a novel antibody\u2013cytokine fusion protein,\u00a0in patients with malignant melanoma or renal cell carcinoma","volume":"17","author":"Rudman","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2019.08.005_bb0165","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00432-012-1327-7","article-title":"Phase I\/II study of the tumour-targeting human monoclonal antibody\u2013cytokine fusion protein L19-TNF in patients with advanced solid tumours","volume":"139","author":"Spitaleri","year":"2013","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0170","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1021\/acs.bioconjchem.8b00548","article-title":"Passive immunotherapies for central nervous system disorders: current delivery challenges and new approaches","volume":"29","author":"Kumar","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.molmed.2019.08.005_bb0175","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1113\/JP275105","article-title":"Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery","volume":"596","author":"Pizzo","year":"2018","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0180","doi-asserted-by":"crossref","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2019.08.005_bb0185","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1021\/mp1003515","article-title":"Receptor-mediated abeta amyloid antibody targeting to Alzheimer\u2019s disease mouse brain","volume":"8","author":"Zhou","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.molmed.2019.08.005_bb0190","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1021\/bc800148t","article-title":"Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses","volume":"19","author":"Pardridge","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.molmed.2019.08.005_bb0195","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ymgme.2018.12.186","article-title":"Preclinical studies of a brain penetrating IgG Trojan horse\u2013arylsulfatase fusion protein in the metachromatic leukodystrophy mouse","volume":"126","author":"Hui","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.molmed.2019.08.005_bb0200","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.brainres.2010.06.059","article-title":"Intravenous treatment of experimental Parkinson\u2019s disease in the mouse\u00a0with\u00a0an IgG\u2013GDNF fusion protein that penetrates the blood\u2013brain barrier","volume":"1352","author":"Fu","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.molmed.2019.08.005_bb0205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1021\/bc900382q","article-title":"Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase","volume":"21","author":"Lu","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.molmed.2019.08.005_bb0210","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.ymgme.2018.12.174","article-title":"Improved brain uptake and efficacy of iduronate 2-sulfatase with the enzyme transport vehicle","volume":"126","author":"Henry","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.molmed.2019.08.005_bb0215","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1124\/jpet.109.165092","article-title":"Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse","volume":"333","author":"Boado","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2019.08.005_bb0220","doi-asserted-by":"crossref","first-page":"P70","DOI":"10.1016\/j.neuron.2015.11.024","article-title":"Discovery of novel blood\u2013brain barrier targets to enhance brain uptake of therapeutic antibodies","volume":"89","author":"Zuchero","year":"2016","journal-title":"Neuron."},{"key":"10.1016\/j.molmed.2019.08.005_bb0225","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1080\/10428190701272264","article-title":"New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicity in\u00a0vivo","volume":"48","author":"Braschoss","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.molmed.2019.08.005_bb0230","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/protein\/gzt065","article-title":"Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells","volume":"27","author":"D\u2019Avino","year":"2014","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.molmed.2019.08.005_bb0235","doi-asserted-by":"crossref","first-page":"87016","DOI":"10.18632\/oncotarget.13522","article-title":"A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy","volume":"7","author":"D\u2019Avino","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.molmed.2019.08.005_bb0240","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0014-5793(02)02527-9","article-title":"A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells","volume":"516","author":"De Lorenzo","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.molmed.2019.08.005_bb0245","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.canlet.2016.02.020","article-title":"A novel fully-human cytolytic fusion protein based on granzyme B shows in\u00a0vitro cytotoxicity and ex\u00a0vivo binding to solid tumors overexpressing the epidermal growth factor receptor","volume":"374","author":"Niesen","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.molmed.2019.08.005_bb0250","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1038\/bcj.2013.4","article-title":"Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model","volume":"3","author":"Schiffer","year":"2013","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.molmed.2019.08.005_bb0255","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1535-7163.MCT-15-0685","article-title":"A novel recombinant Anti-CD22 immunokinase delivers proapoptotic activity of death-associated protein kinase (DAPK) and mediates cytotoxicity in neoplastic B cells","volume":"15","author":"Linienthal","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.molmed.2019.08.005_bb0260","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1080\/07357900802427935","article-title":"A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma","volume":"27","author":"Wang","year":"2009","journal-title":"Cancer Investig."},{"key":"10.1016\/j.molmed.2019.08.005_bb0265","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4049\/jimmunol.173.1.61","article-title":"A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors","volume":"173","author":"Xu","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0270","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2174\/138920108784567326","article-title":"Design of cytotoxic ribonucleases by cationization to enhance intracellular protein delivery","volume":"9","author":"Futami","year":"2008","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0275","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/protein\/gzi073","article-title":"Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition","volume":"19","author":"Erickson","year":"2006","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.molmed.2019.08.005_bb0280","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.biochi.2008.01.010","article-title":"RNase-induced apoptosis: fate of calcium-activated potassium channels","volume":"90","author":"Ilinskaya","year":"2008","journal-title":"Biochimie"},{"key":"10.1016\/j.molmed.2019.08.005_bb0285","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1210\/jc.2002-020373","article-title":"Antineoplastic ribonucleases selectively kill thyroid carcinoma cells via caspase-mediated induction of apoptosis","volume":"88","author":"Spalletti-Cernia","year":"2003","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2019.08.005_bb0290","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1380-2933(97)00070-5","article-title":"Cloning and cytotoxicity of a human pancreatic RNase immunofusion","volume":"3","author":"Zewe","year":"1997","journal-title":"Immunotechnology."},{"key":"10.1016\/j.molmed.2019.08.005_bb0295","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bjh.14971","article-title":"Elimination of different leukaemia subtypes using novel CD89-specific human cytolytic fusion proteins","volume":"183","author":"Gresch","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0300","doi-asserted-by":"crossref","first-page":"561814","DOI":"10.1155\/2015\/561814","article-title":"A humanized anti-CD22\u2013onconase antibody\u2013drug conjugate mediates highly potent destruction of targeted tumor cells","volume":"2015","author":"Weber","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.molmed.2019.08.005_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002434","article-title":"Barnase as a new therapeutic agent triggering apoptosis in human cancer cells","volume":"3","author":"Edelweiss","year":"2008","journal-title":"PLOS One"},{"key":"10.1016\/j.molmed.2019.08.005_bb0310","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2017.09.009","article-title":"Antibody directed enzyme prodrug therapy (ADEPT): trials and tribulations","volume":"118","author":"Sharma","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molmed.2019.08.005_bb0315","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2217\/imt.10.90","article-title":"Antibody\u2013enzyme fusion proteins for cancer therapy","volume":"3","author":"Andrady","year":"2011","journal-title":"Immunotherapy."},{"key":"10.1016\/j.molmed.2019.08.005_bb0320","first-page":"814","article-title":"A Phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody\u2013enzyme fusion protein MFECP1 and a bis-iodophenol mustard prodrug","volume":"11","author":"Mayer","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2019.08.005_bb0325","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ymgme.2018.11.011","article-title":"Enzyme enhancement therapeutics for lysosomal storage diseases: current status and perspective","volume":"126","author":"Thomas","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.molmed.2019.08.005_bb0330","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S139601","article-title":"Development\u00a0of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future","volume":"11","author":"Whiteman","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.molmed.2019.08.005_bb0335","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet. Med."},{"key":"10.1016\/j.molmed.2019.08.005_bb0340","first-page":"107","article-title":"Mucopolysaccharidosis type II, Hunter\u2019s syndrome","volume":"12","author":"Tylki-Szyma\u0144ska","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.molmed.2019.08.005_bb0345","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A blood\u2013brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2019.08.005_bb0350","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/bit.25289","article-title":"Insulin receptor antibody\u2013iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in rhesus monkeys","volume":"111","author":"Boado","year":"2014","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.molmed.2019.08.005_bb0355","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/bit.23118","article-title":"Expression in CHO cells and pharmacokinetics and brain uptake in the rhesus monkey of an IgG\u2013iduronate-2-sulfatase fusion protein","volume":"108","author":"Lu","year":"2011","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.molmed.2019.08.005_bb0360","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13023-018-0849-8","article-title":"Neurocognitive and somatic stabilization in pediatric patients with severe mucopolysaccharidosis type I after 52\u00a0weeks of intravenous brain-penetrating insulin receptor antibody\u2013iduronidase fusion protein (valanafusp alpha): an open label phase 1\u20132 trial","volume":"13","author":"Giugliani","year":"2018","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.molmed.2019.08.005_bb0365","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1021\/acs.molpharmaceut.6b00037","article-title":"Insulin receptor antibody\u2013alpha-N-acetylglucosaminidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in sanfilippo type B fibroblasts","volume":"13","author":"Boado","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.molmed.2019.08.005_bb0370","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/271067a0","article-title":"Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors","volume":"271","author":"Alarcon-Segovia","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2019.08.005_bb0375","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/art.1780300610","article-title":"Monoclonal murine anti-DNA antibody interacts with living mononuclear cells","volume":"30","author":"Okudaira","year":"1987","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2019.08.005_bb0380","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1212\/WNL.41.11.1757","article-title":"Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis\/sensory neuronopathy","volume":"41","author":"Dalmau","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2019.08.005_bb0385","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1126\/science.126.3265.162","article-title":"Affinity between the lupus erythematosus serum factor and\u00a0cell nuclei and nucleoprotein","volume":"126","author":"Holman","year":"1957","journal-title":"Science"},{"key":"10.1016\/j.molmed.2019.08.005_bb0390","first-page":"364","article-title":"Antibody penetration into living cells. I. Intranuclear immunoglobulin in peripheral blood mononuclear cells in mixed connective tissue disease and systemic lupus eruthematosus","volume":"35","author":"Alarcon-Segovia","year":"1979","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0395","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.4049\/jimmunol.157.5.2082","article-title":"Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody","volume":"157","author":"Zack","year":"1996","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0400","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.4049\/jimmunol.144.7.2653","article-title":"A conserved anti-DNA antibody idiotype associated with nephritis in murine and human systemic lupus erythematosus","volume":"144","author":"Weisbart","year":"1990","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0405","doi-asserted-by":"crossref","first-page":"20790","DOI":"10.1074\/jbc.C700090200","article-title":"Intranuclear protein transduction through a nucleoside salvage pathway","volume":"282","author":"Hansen","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.molmed.2019.08.005_bb0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep12022","article-title":"DNA-dependent targeting of cell nuclei by a lupus autoantibody","volume":"5","author":"Weisbart","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2019.08.005_bb0415","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004385","article-title":"Targeting cancer with a lupus autoantibody","volume":"4","author":"Hansen","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2019.08.005_bb0420","doi-asserted-by":"crossref","first-page":"11782","DOI":"10.1093\/nar\/gkx871","article-title":"A cell-penetrating antibody inhibits human RAD51 via direct binding","volume":"45","author":"Turchick","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molmed.2019.08.005_bb0425","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/0008-5472.CAN-14-2278","article-title":"Optimizing a lupus autoantibody for targeted cancer therapy","volume":"75","author":"Noble","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2019.08.005_bb0430","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.18632\/oncotarget.26654","article-title":"Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells","volume":"10","author":"Turchick","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.molmed.2019.08.005_bb0435","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/j.molmed.2019.08.005_bb0440","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/1535-7163.MCT-12-0476-T","article-title":"A cell-penetrating bispecific antibody for therapeutic regulation of intracellular targets","volume":"11","author":"Weisbart","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.molmed.2019.08.005_bb0445","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ijc.29685","article-title":"Combining intracellular antibodies to restore function of mutated p53 in cancer","volume":"138","author":"Chan","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.molmed.2019.08.005_bb0450","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1100\/tsw.2005.98","article-title":"Antibody mediated transduction of therapeutic proteins into living cells","volume":"5","author":"Hansen","year":"2005","journal-title":"Sci. World J."},{"key":"10.1016\/j.molmed.2019.08.005_bb0455","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1006\/jaut.1998.0212","article-title":"An autoantibody is modified for use as a delivery system to target the cell nucleus: therapeutic implications","volume":"11","author":"Weisbart","year":"1998","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.molmed.2019.08.005_bb0460","first-page":"1867","article-title":"Antibody-mediated transduction of p53 selectively kills cancer cells","volume":"25","author":"Weisbart","year":"2004","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0465","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1158\/0008-5472.CAN-06-3783","article-title":"Antibody-mediated p53 protein therapy prevents liver metastasis in\u00a0vivo","volume":"67","author":"Hansen","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2019.08.005_bb0470","first-page":"167","article-title":"Antibody-mediated FOXP3 protein therapy induces apoptosis in cancer cells in\u00a0vitro and inhibits metastasis in\u00a0vivo","volume":"35","author":"Heinze","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0475","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/10611860400029002","article-title":"An intracellular delivery vehicle for protein transduction of micro-dystrophin","volume":"13","author":"Weisbart","year":"2005","journal-title":"J.\u00a0Drug Target."},{"key":"10.1016\/j.molmed.2019.08.005_bb0480","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.brainres.2006.03.025","article-title":"Antibody-mediated Hsp70 protein therapy","volume":"1088","author":"Hansen","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.molmed.2019.08.005_bb0485","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/hmg\/ddt003","article-title":"Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopothy","volume":"22","author":"Lawlor","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2019.08.005_bb0490","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/hmg\/ddu024","article-title":"Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease","volume":"23","author":"Duran","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2019.08.005_bb0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pgen.1002037","article-title":"PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease","volume":"7","author":"Turnbull","year":"2011","journal-title":"PLoS Genet."},{"key":"10.1016\/j.molmed.2019.08.005_bb0500","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/hmg\/ddp535","article-title":"Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease","volume":"19","author":"Douillard-Guilloux","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2019.08.005_bb0505","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ana.24104","article-title":"PTG protein depletion rescues malin-deficient Lafora disease in mouse","volume":"75","author":"Turnbull","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0510","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2019.08.005_bb0515","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","article-title":"Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease","volume":"79","author":"Martiniuk","year":"1998","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.molmed.2019.08.005_bb0520","first-page":"91","article-title":"Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency","volume":"2","author":"Ausems","year":"1999","journal-title":"Community Genet."},{"key":"10.1016\/j.molmed.2019.08.005_bb0525","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"Ausems","year":"1999","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2019.08.005_bb0530","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125358","article-title":"Improved efficacy of a next-generation ERT in murine Pompe disease","volume":"4","author":"Xu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.molmed.2019.08.005_bb0535","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00109-017-1505-9","article-title":"Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease","volume":"95","author":"Yi","year":"2017","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.molmed.2019.08.005_bb0540","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.molmed.2019.08.005_bb0545","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.20019","article-title":"Enzyme replacement therapy in late-onset Pompe\u2019s disease: a three-year follow-up","volume":"55","author":"Winkel","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0550","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab. Investig."},{"key":"10.1016\/j.molmed.2019.08.005_bb0555","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1750-1172-8-90","article-title":"Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy","volume":"8","author":"Prater","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.molmed.2019.08.005_bb0560","first-page":"424","article-title":"Expression of the insulin-like growth factor-II\/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy","volume":"75","author":"Funk","year":"1992","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2019.08.005_bb0565","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.molmed.2019.08.005_bb0570","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid \u03b1-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2019.08.005_bb0575","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.ymgme.2017.12.028","article-title":"Next-generation antibody-guided enzyme replacement therapy in Pompe disease mice","volume":"123","author":"Baik","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.molmed.2019.08.005_bb0580","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1073\/pnas.93.1.65","article-title":"High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease","volume":"93","author":"Van Hove","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2019.08.005_bb0585","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF02889849","article-title":"Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture","volume":"45","author":"Griffin","year":"1984","journal-title":"Virchows Arch. B. Cell Pathol. Incl. Mol. Pathol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0590","first-page":"123","article-title":"Pathology of skeletal muscle cells in adult-onset glycogenosis type II (Pompe disease): ultrastructural study","volume":"46","author":"Lewandowska","year":"2008","journal-title":"Folia Neuropathol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0595","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.ymgme.2018.12.211","article-title":"Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease","volume":"126","author":"Kishnani","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.molmed.2019.08.005_bb0600","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1074\/jbc.273.9.5288","article-title":"Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line","volume":"273","author":"Crawford","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.molmed.2019.08.005_bb0605","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1074\/jbc.R117.803064","article-title":"Lafora disease offers a unique window into neuronal glycogen metabolism","volume":"293","author":"Gentry","year":"2018","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.molmed.2019.08.005_bb0610","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081743","article-title":"Pathogenesis of Lafora disease: transition of soluble glycogen to insoluble polyglucosan","volume":"18","author":"Sullivan","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2019.08.005_bb0615","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.yebeh.2018.11.014","article-title":"The 4th International Lafora Epilepsy Workshop: shifting paradigms, paths to treatment, and hope for patients","volume":"90","author":"Brewer","year":"2019","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.molmed.2019.08.005_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2019.07.002","article-title":"Targeting pathogenic Lafora bodies in Lafora disease using an antibody\u2013enzyme fusion","author":"Brewer","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2019.08.005_bb0625","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.9b00396","article-title":"Central nervous system delivery and biodistribution analysis of an antibody\u2013enzyme fusion for the treatment of Lafora disease","author":"Austin","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.molmed.2019.08.005_bb0630","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ymgme.2018.05.003","article-title":"Best practices for the use of intracerebroventricular drug delivery devices","volume":"124","author":"Slavc","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.molmed.2019.08.005_bb0635","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.clim.2018.09.003","article-title":"Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: results from a Phase 1\/2 study","volume":"197","author":"Cherukuri","year":"2018","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1369\/jhc.2008.952770","article-title":"A guide to the perplexed on the specificity of antibodies","volume":"57","author":"Saper","year":"2009","journal-title":"J.\u00a0Histochem. Cytochem."},{"key":"10.1016\/j.molmed.2019.08.005_bb0645","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/jnr.24386","article-title":"Glycogen distribution in\u00a0mouse hippocampus","volume":"97","author":"Hirase","year":"2019","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.molmed.2019.08.005_bb0650","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/19420862.2018.1556465","article-title":"Antibodies to watch in 2019","volume":"11","author":"Kaplon","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.molmed.2019.08.005_bb0655","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2014.10.034","article-title":"Probing the extracellular diffusion of antibodies in brain using in\u00a0vivo integrative optical imaging and ex\u00a0vivo fluorescence imaging","volume":"197","author":"Wolak","year":"2015","journal-title":"J Cont Rel."},{"key":"10.1016\/j.molmed.2019.08.005_bb0660","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nbt1142","article-title":"Engineered antibody fragments and the rise of single domains","volume":"23","author":"Holliger","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2019.08.005_bb0665","doi-asserted-by":"crossref","first-page":"313","DOI":"10.21037\/atm.2018.06.52","article-title":"Pompe disease: how to solve many problems with one solution","volume":"6","author":"Puertollano","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.molmed.2019.08.005_bb0670","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1093\/hmg\/ddn292","article-title":"Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease","volume":"17","author":"Raben","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2019.08.005_bb0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040776","article-title":"The pharmacological chaperone AT2220 increases recombinant human acid \u03b1-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease","volume":"7","author":"Khanna","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2019.08.005_bb0680","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam6375","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase","volume":"9","author":"Puzzo","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2019.08.005_bb0685","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.57","article-title":"Antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of pompe disease","volume":"3","author":"Clayton","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.molmed.2019.08.005_bb0690","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/hmg\/8.2.345","article-title":"A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2)","volume":"8","author":"Serratosa","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2019.08.005_bb0695","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/ng1238","article-title":"Mutations in NHLRC1 cause progressive myoclonus epilepsy","volume":"35","author":"Chan","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2019.08.005_bb0700","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/iub.1072","article-title":"Deciphering the role of malin in the Lafora progressive myoclonus epilepsy","volume":"64","author":"Rom\u00e1-Mateo","year":"2012","journal-title":"IUBMB Life"},{"key":"10.1016\/j.molmed.2019.08.005_bb0705","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/glia.23463","article-title":"Astrocytes and neurons produce distinct types of polyglucosan bodies in Lafora disease","volume":"66","author":"Aug\u00e9","year":"2018","journal-title":"Glia"},{"key":"10.1016\/j.molmed.2019.08.005_bb0710","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/hmg\/ddy044","article-title":"Astrocytes: new players in progressive myoclonus epilepsy of Lafora type","volume":"27","author":"Rubio-Villena","year":"2018","journal-title":"Hum. Mol. Genet."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491419302266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491419302266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:19:45Z","timestamp":1761463185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491419302266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":142,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1471491419302266"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2019.08.005","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-Mediated Enzyme Therapeutics and Applications in Glycogen Storage Diseases","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2019.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}